Abstract
Nitric oxide (NO) plays a critical role in acute and
chronic inflammation. NO’s contributions to cancer are of particular interest
due to its context-dependent bioactivities. For example, immune cells initially
produce cytotoxic quantities of NO in response to the nascent tumor. However,
it is believed that this fades over time and reaches a concentration that
supports the tumor microenvironment (TME). These complex dynamics are further
complicated by other factors, such as diet and oxygenation, making it
challenging to establish a complete picture of NO’s impact on tumor progression.
Although many activity-based sensing (ABS) probes for NO have been developed,
only a small fraction have been employed in vivo and fewer yet are
practical in cancer models where the NO concentration is < 200 nM. To overcome
this outstanding challenge, we have developed BL660-NO, the first ABS
probe for NIR bioluminescence imaging of NO in cancer. Owing to the low intrinsic
background, high sensitivity, and deep tissue imaging capabilities of our
design, BL660-NO was successfully employed to visualize endogenous NO
in cellular systems, a human liver metastasis model, and a murine breast cancer
model. Importantly,
its exceptional performance facilitated the design of a dietary study to examine
the impact of NO on the TME by varying the intake of fat. BL660-NO provides
the first direct molecular evidence that intratumoral NO becomes elevated in mice
fed a high-fat diet who became obese with larger tumors compared to control
animals on a low-fat diet. These results indicate that an inflammatory diet can
increase NO production via recruitment of macrophages and overexpression of iNOS which
in turn can drive tumor progression.